Target intelligence / Profile preview

Medium-chain triglyceride metabolism (MCT metabolism) (MCT metabolism)

Target
MCT metabolism
Molecular classification
Other
01

Overview

Medium-chain triglyceride (MCT) metabolism refers to the biochemical pathway responsible for the breakdown and utilization of fats containing 6 to 12 carbon atoms. Unlike long-chain triglycerides, MCTs are rapidly hydrolyzed by lipases and absorbed directly into the portal circulation, where they are transported to the liver for oxidation (StatPearls, NBK541057). Within the mitochondria, they undergo beta-oxidation, primarily mediated by the enzyme medium-chain acyl-CoA dehydrogenase (MCAD), encoded by the ACADM gene (UniProt, P11310). This process is a critical source of energy, especially during fasting or increased energy demand, and produces ketone bodies that can serve as an alternative fuel for the brain. Dysregulation or genetic deficiencies in this pathway, such as MCAD deficiency, can lead to severe metabolic crises, hypoglycemia, and neurological impairment (PubMed, 20301597). Therapeutically, MCTs are administered as medical foods or supplements to manage malabsorption, epilepsy, and certain neurodegenerative conditions like Alzheimer's disease by providing a readily available energy source (PubMed, 29078846).

Other names
MCT metabolismMedium-chain fatty acid oxidationMCFA metabolismMedium-chain fatty acid beta-oxidation
02

Mechanism of action

Provision of rapidly absorbable fatty acids for mitochondrial beta-oxidation and ketone body production, bypassing long-chain fatty acid transport mechanisms.

03

Biological functions

Lipid metabolismEnergy productionMitochondrial beta-oxidationKetogenesis
04

Disease associations

Medium-chain acyl-CoA dehydrogenase deficiencyMalabsorption syndromesEpilepsyAlzheimer's diseaseLong-chain fatty acid oxidation disorders (LC-FAOD)
05

Safety considerations

Gastrointestinal distress (diarrhea, abdominal cramping)Risk of metabolic acidosisContraindicated in patients with MCAD deficiencyPotential for medium-chain fatty acid toxicity in specific metabolic contexts
06

Interacting drugs

Medium-chain triglycerides (MCT oil)

3 more in the full profile.

07

Biomarkers

Octanoylcarnitine (C8)Hexanoylcarnitine (C6)Decanoylcarnitine (C10)Medium-chain dicarboxylic acids (adipic, suberic, sebacic acids)

Beyond the preview

Go deeper on Medium-chain triglyceride metabolism (MCT metabolism) (MCT metabolism).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Medium-chain triglyceride metabolism (MCT metabolism) (MCT metabolism).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call